221050-88-0

Basic information

• Product Name: tert-Butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate
• Synonyms: tert-Butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate;1-Boc-4-(2-chloropyrimidin-4-yl)piperazine;2-Chloro-4-(4-Boc-1-piperazinyl)pyriMidine;2-Chloro-4-[1-(4-tert-butoxycarbonyl)piperazinyl]pyrimidine;4-(2-Chloropyrimidin-4-yl)piperazine-1-carboxylic acid tert-butyl ester;tert-Butyl 4-(2-Chloro-4-pyrimidinyl)-1-piperazinecarboxylate;tert-Butyl 4-(2-chloropyrimidin-4-yl)
• CAS NO: 221050-88-0
• Molecular Formula: C₁₃H₁₉ClN₄O₂
• Molecular Weight: 298.77
• Product Categories: pharmacetical
• Mol File: 221050-88-0.mol

Chemical Properties

• Boiling Point: 451.8ºC at 760 mmHg
• Flash Point: 227ºC
• Appearance: /
• Density: 1.253g/cm3
• Vapor Pressure: 2.37E-08mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 4.51±0.31(Predicted)
• CAS DataBase Reference: tert-Butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate(221050-88-0)
• EPA Substance Registry System: tert-Butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate(221050-88-0)

Safety Data

• Hazardous Substances Data: 221050-88-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Tert-butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the creation of drugs with specific therapeutic properties, such as antipsychotic and antihistaminic medications, which are crucial for treating a variety of mental health and allergic conditions.
Used in Drug Discovery and Development:
In the realm of drug discovery, tert-butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate is employed as a valuable compound for exploring new therapeutic agents. Its potential as an anti-tumor agent is currently under investigation, which could lead to advancements in cancer treatment by providing novel options for patients.
Used in Medicinal Chemistry Research:
Tert-butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate is also used as a research tool in medicinal chemistry. Scientists leverage its properties to study the mechanisms of action of potential drugs, optimize their efficacy, and understand their interactions with biological targets, thereby contributing to the advancement of pharmaceutical science.

InChI:InChI=1/C13H19ClN4O2/c1-13(2,3)20-12(19)18-8-6-17(7-9-18)10-4-5-15-11(14)16-10/h4-5H,6-9H2,1-3H3

Upstream product

• 3934-20-1 2,6-Dichloropyrimidine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 7461-50-9 2-chloropyrimidin-4-amine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 479691-58-2 4-[2-(3-chloro-benzylamino)-pyrimidin-4-yl]-piperazine-1-carboxylic acid tert-butyl ester 
• 479690-80-7 4-[2-(3,5-difluoro-benzyloxy)-pyrimidin-4-yl]-piperazine-1-carboxylic acid tert-butyl ester 
• 1143576-96-8 tert-butyl 4-[2-(2,3-difluorophenyl)pyrimidin-4-yl]piperazine-1-carboxylate 
• 1143578-22-6 tert-butyl 4-(2-phenylpyrimidin-4-yl)piperazine-1-carboxylate 
• 1143576-85-5 tert-butyl 4-[2-(2,4-difluorophenyl)pyrimidin-4-yl]piperazine-1-carboxylate 
• 1092569-07-7 tert-butyl 4-[2-(3-hydroxymethylphenyl)pyrimidin-4-yl]piperazine-1-carboxylate 
• 1323917-69-6 2-(2-fluoro-phenyl)-4-{5-[4-(4-methyl-piperazin-1-yl)-pyrimidin-2-yl]-pyridin-3-yl}-[1,8]naphthyridine 
• 1323917-70-9 2-(2-fluoro-phenyl)-4-[5-(4-piperazin-1-yl-pyrimidin-2-yl)-pyridin-3-yl]-[1,8]naphthyridine 
• 1323920-03-1 C₃₂H₃₀FN₇O₂ 
• 1378368-15-0 tert-butyl 4-(2-(3-(tert-butyl)-4-(cyclopentylamino)phenyl)pyrimidin-4-yl)piperazine-1-carboxylate 
• 1143577-38-1 tert-butyl 4-[6-(2,4-difluorophenyl)pyrimidin-4-yl]piperazine-1-carboxylate 
• 1143577-39-2 4-(2,4-difluorophenyl)-6-(piperazin-1-yl)pyrimidine 
• 1143577-41-6 4-[6-(2,4-difluorophenyl)pyrimidin-4-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide 
• 1143576-86-6 2-(2,4-difluorophenyl)-4-(piperazin-1-yl)pyrimidine 

Relevant articles and documents

GLP-1R AGONISTS AND USES THEREOF

Provided are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE

The present invention relates to compounds of formula (I), wherein R1 to R3, n and A are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

UR-DEBa176: A 2,4-Diaminopyrimidine-Type Radioligand Enabling Binding Studies at the Human, Mouse, and Rat Histamine H4 Receptors

Differences in sequence homology between human (h), mouse (m), and rat (r) histamine H4 receptors (H4R) cause discrepancies regarding affinities, potencies, and/or efficacies of ligands and therefore compromise translational animal models and the applicability of radioligands. Aiming at a radioligand enabling robust and comparative binding studies at the h/m/rH4Rs, 2,4-diaminopyrimidines were synthesized and pharmacologically investigated. The most notable compounds identified were two (partial) agonists with comparable potencies at the h/m/rH4Rs: UR-DEBa148 (N-neopentyl-4-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)pyrimidin-2-amine bis(2,2,2-trifluoroacetate), 43), the most potent [pEC50 (reporter gene assay) = 9.9/9.6/10.3] compound in the series being slightly G-protein biased and UR-DEBa176 [(R)-4-[3-(dimethylamino)pyrrolidin-1-yl]-N-neopentylpyrimidin-2-amine bis(2,2,2-trifluoroacetate), 46, pEC50 (reporter gene assay) = 8.7/9.0/9.2], a potential "cold" form of a tritiated H4R ligand. After radiolabeling, binding studies with [3H]UR-DEBa176 ([3H]46) at the h/m/rH4Rs revealed comparable Kd values (41/17/22 nM), low nonspecific binding (11-17%, aKd), and fast associations/dissociations (25-30 min) and disclosed [3H]UR-DEBa176 as useful molecular tool to determine h/m/rH4R binding affinities for H4R ligands.

Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3

Hybridization strategy is an effective strategy to obtain multi-target inhibitors in drug design. In this study, we assembled the pharmacophores of momelotinib and tandutinib to get a series of 4-piperazinyl-2-aminopyrimidine derivatives. All compounds were tested for the inhibition of JAK2 and FLT3 enzymes, of which, compounds with potent enzyme activities were assayed for antiproliferative activities against three cancer cell lines (HEL, MV4-11, and HL60). The structure-activity relationship studies were conducted through variations in two regions, the “A” phenyl ring and “B” phenyl ring. Compound 14j showed the most balanced in vitro inhibitory activity against JAK2 and FLT3 (JAK2 IC50 = 27 nM, FLT3 IC50 = 30 nM), and it also showed potent inhibition against the above tested cell lines. In the cellular context, 14j strongly induced apoptosis by arresting cell cycle in the G1/S phase, and was selected as a promising JAK2/FLT3 dual inhibitor.

2 - Amino pyrimidine compounds and their use (by machine translation)

The invention belongs to the technical field of pharmaceutical chemical synthesis, relates to the general formula (I) indicated by the 2 - amino pyrimidine compounds and their pharmaceutically acceptable salt, solvate or prodrug, their method of preparation and containing pharmaceutical composition of said compound, wherein substituent R1 , R2 , R6 With the meanings given in the specification. The invention also relates to the compounds of the formula I or its pharmaceutical composition for treating and/or preventing malignant blood diseases or other proliferative diseases in the use of the medicament. (by machine translation)

Alpha,beta-unsaturated ketone compound containing aromatic heterocycles and preparation method and application thereof

The invention provides an alpha,beta-unsaturated ketone compound containing aromatic heterocycles and a preparation method and an application thereof. The compound has strong anti-tumor activity, andhas a structure represented by the formula (I) defined in the specification.

Aminomethyl-containing piperazinone compound as well as preparation method and application thereof

The invention discloses an aminomethyl-containing piperazinone compound as well as a preparation method and application thereof. The compound has a structure shown as a general formula (I). The invention further provides the preparation method and the application of the compound. The compound disclosed by the invention has certain activity of inhibiting AKT1 kinase and activity of inhibiting the growth of PC-3 tumor cells, and is used for preparing an anti-tumor medicine. The formula I is shown in the description.

Pd/PTABS: Catalyst for Room Temperature Amination of Heteroarenes

A mild and highly efficient catalytic amination procedure for chloroheteroarenes at ambient temperature using the Pd/PTABS catalytic system is reported. The protocol is selective for the amination of chloroheteroarenes using secondary amines such as piperidine, pyrrolidine, and several others. The exceptional mildness of the developed protocol is beneficial for the synthesis of a crucial Buparlisib intermediate as well as the formal synthesis of Alogliptin in competitive yields.

BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2

The present invention directs to a compound represented by formula (I).

Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors

A series of piperazine ureas were designed, synthesized, and evaluated for their potential as novel orally efficacious fatty acid amide hydrolase (FAAH) inhibitors for the treatment of neuropathic and inflammatory pain. We carried out an optimization stud